Yohann Repessé
YOU?
Author Swipe
View article: Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing Study
Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing Study Open
Introduction Although clinical experience of a triple‐secured, plasma‐derived, von Willebrand factor (pdVWF), almost devoid of Factor VIII (FVIII) in adults with von Willebrand disease (VWD), is widely reported, its use in children is less…
View article: Navigating the Transition From Adolescence to Adulthood Among Young People With Severe Haemophilia: The Qualitative Phase of the TRANSHEMO Project
Navigating the Transition From Adolescence to Adulthood Among Young People With Severe Haemophilia: The Qualitative Phase of the TRANSHEMO Project Open
Introduction Haemophilia causes spontaneous or prolonged bleeding due to a deficiency in clotting factor VIII (haemophilia A) or IX (haemophilia B). Although substitutive therapies and regular follow‐up can prevent severe haemorrhagic even…
View article: Health-related quality of life in children with von Willebrand disease: results of the French real-life Willebrand Study Health-related Quality of Life study
Health-related quality of life in children with von Willebrand disease: results of the French real-life Willebrand Study Health-related Quality of Life study Open
HRQoL was reduced in French VWD children and their families secondary to physical, mental, and social health impacts, especially (but not only) in adolescents and in children with severe VWD types.
View article: Impact of Systematic Joint Examination (Ultrasound, Functional and Physical) on Treatment Management Decisions in Patients With Haemophilia A in France: Final Data From the Prospective, Observational A‐MOVE Study
Impact of Systematic Joint Examination (Ultrasound, Functional and Physical) on Treatment Management Decisions in Patients With Haemophilia A in France: Final Data From the Prospective, Observational A‐MOVE Study Open
Background Haemophilia management aims to prevent bleeding and preserve joint function. Changes in patients’ joint health may influence physicians' decisions to adjust treatment. The Haemophilia Joint Health Score (HJHS) and Haemophilia Ea…
View article: Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)
Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST) Open
The Hemophilia Functional Ability Scoring Tool (Hemo-FAST), consisting of a patient-reported outcome (PRO) part and a clinician-reported outcome (ClinRO) part, was developed as a rapid and effective tool to assess functional mobility in cl…
View article: Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France
Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France Open
Background: More real-world data are needed to complement existing phase III studies on the efficacy and safety of recombinant factor IX Fc fusion protein (rFIXFc) in people with haemophilia B. Objectives: We report final data from the B-S…
View article: Congenital Haemostasis Disorders and Urology Surgery: Is It Safe?
Congenital Haemostasis Disorders and Urology Surgery: Is It Safe? Open
Background: There are no specific recommendations for the management of patients with bleeding disorders (BD), such as haemophilia A (HA), haemophilia B (HB), or von Willebrand disease (WD), in urology surgery. Methods: We conducted a retr…
View article: PB0638 Final Data from A-MOVE: 12-Month Prospective Multicentre Study to Investigate the Impact of Systematic Joint Examination on Treatment Management Decisions in Patients with Hemophilia A in France
PB0638 Final Data from A-MOVE: 12-Month Prospective Multicentre Study to Investigate the Impact of Systematic Joint Examination on Treatment Management Decisions in Patients with Hemophilia A in France Open
data demonstrate the clinical efficacy of prophylactic octocog alfa for preventing bleeds in patients with severe HA and pre existing target joints.
View article: Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross‐sectional study based on the FranceCoag registry
Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): A multicentric French national observational cross‐sectional study based on the FranceCoag registry Open
Introduction It is necessary to gain insights into adherence to healthcare in people with severe haemophilia (PwSH), especially during the transition from paediatric to adult care, which is an important phase in lives of young people with …
View article: A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis
A French Real-World Evidence Study Evaluating the Efficacy, Safety, and Pharmacokinetic Parameters of rVIII-SingleChain in Patients with Hemophilia A Receiving Prophylaxis Open
Background rVIII-SingleChain is a recombinant factor VIII (FVIII) with increased binding affinity to von Willebrand factor compared with other FVIII products. rVIII-SingleChain is indicated for the treatment and prevention of bleeding epis…
View article: Effectiveness of long‐term prophylaxis using <scp>pdFVIII</scp>/<scp>VWF</scp> concentrate in patients with inherited von Willebrand disease
Effectiveness of long‐term prophylaxis using <span>pdFVIII</span>/<span>VWF</span> concentrate in patients with inherited von Willebrand disease Open
Background Patients with symptomatic von Willebrand disease (VWD) should be offered long‐term prophylaxis (LTP) to prevent recurrent bleedings. Our objective was to evaluate the effectiveness and safety of Voncento®, a plasma‐derived FVIII…
View article: Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders
Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders Open
Hairy cell leukemia (HCL) is characterized by abnormal villous lymphoid cells that express CD103, CD123, CD25 and CD11c. HCL-like disorders, including hairy cell leukemia variant (vHCL) and splenic diffuse red pulp lymphoma (SDRPL), have s…
View article: IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans
IVIg increases interleukin-11 levels, which in turn contribute to increased platelets, VWF and FVIII in mice and humans Open
Summary The mechanisms of action of intravenous immunoglobulins (IVIg) in autoimmune diseases are not fully understood. The fixed duration of efficacy and noncumulative effects of IVIg in immune thrombocytopenia (ITP) and acquired von Will…
View article: Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?
Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life? Open
We retrospectively analysed the data files of 171 adults and 87 children/adolescents with severe haemophilia, except for 14 patients (moderate; minor) (1), to develop a global population pharmacokinetic (PK) model for eight factors VIII (F…
View article: Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A
Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A Open
Replacement therapy in severe hemophilia A leads to factor VIII (FVIII) inhibitors in 30% of patients. Factor VIII gene (F8) mutation type, a family history of inhibitors, ethnicity and intensity of treatment are established risk factors, …
View article: Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A
Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A Open
International audience
View article: Point of Care Tests VerifyNow P2Y12 and INNOVANCE PFA P2Y Compared to Light Transmittance Aggregometry After Fibrinolysis
Point of Care Tests VerifyNow P2Y12 and INNOVANCE PFA P2Y Compared to Light Transmittance Aggregometry After Fibrinolysis Open
Detection of high on-treatment platelet reactivity (HPR) by point-of-care tests has not been validated after successful fibrinolysis for ST-elevation myocardial infarction. We assessed the validity of the point-of-care VerifyNow P2Y12 (VN)…
View article: Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice
Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice Open
Cancer patients display cognitive impairment due, at least partly, to the treatments. Additionally, chemotherapeutic treatments can lead to organ injury, limiting their use, and are likely to have negative impacts on patients' quality of l…
View article: Potent Thrombolytic Effect of <i>N</i> -Acetylcysteine on Arterial Thrombi
Potent Thrombolytic Effect of <i>N</i> -Acetylcysteine on Arterial Thrombi Open
Background: Platelet cross-linking during arterial thrombosis involves von Willebrand Factor (VWF) multimers. Therefore, proteolysis of VWF appears promising to disaggregate platelet-rich thrombi and restore vessel patency in acute thrombo…
View article: Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia
Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia Open
The treatment of acquired hemophilia (AH) involves discussing whether corticosteroids should be administered alone or combined with immunosuppressant drugs, which increase the risk of infection especially in elderly patients and/or those w…
View article: Impact of Alcohol Consumption on the Outcome of Ischemic Stroke and Thrombolysis
Impact of Alcohol Consumption on the Outcome of Ischemic Stroke and Thrombolysis Open
Background and Purpose— Tissue-type plasminogen activator (tPA) is the only acute treatment for ischemic stroke. Unfortunately, the benefit of tPA-driven thrombolysis is not systematic, and understanding the reasons for this is mandatory. …